Capital International Investors Takes Position in Billiontoone, Inc. $BLLN

Capital International Investors purchased a new stake in shares of Billiontoone, Inc. (NASDAQ:BLLN) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 178,000 shares of the company’s stock, valued at approximately $14,568,000. Capital International Investors owned 0.39% of Billiontoone as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in BLLN. Baillie Gifford & Co. purchased a new stake in shares of Billiontoone during the 4th quarter valued at approximately $103,786,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of Billiontoone during the 4th quarter valued at approximately $13,373,000. Geode Capital Management LLC purchased a new stake in shares of Billiontoone during the 4th quarter valued at approximately $6,716,000. UBS Group AG purchased a new stake in shares of Billiontoone during the 4th quarter valued at approximately $2,586,000. Finally, TD Asset Management Inc purchased a new stake in shares of Billiontoone during the 4th quarter valued at approximately $2,188,000.

Analysts Set New Price Targets

Several research firms have recently commented on BLLN. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. BTIG Research reduced their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings downgraded shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Guggenheim lifted their target price on shares of Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Finally, Wells Fargo & Company dropped their target price on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $125.29.

Billiontoone Stock Up 8.4%

Billiontoone stock opened at $102.39 on Wednesday. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $138.70. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The firm has a 50 day moving average price of $86.68 and a 200 day moving average price of $88.15. The company has a market capitalization of $4.71 billion and a PE ratio of 186.16.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to analyst estimates of $95.81 million. During the same quarter last year, the business posted ($0.39) EPS. The firm’s revenue for the quarter was up 83.8% on a year-over-year basis. Research analysts expect that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Billiontoone Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.